TrialThe oncologist2022

Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601).

Jin Matsuyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.